Patients with severe heart arrhythmias are at risk of dying within months without the aid of a pacemaker. In India many heart patients are unable to afford the device. Reusing devices from deceased Americans has been found to be a safe and efficient option.

Patients with a common heart arrhythmia called atrial fibrillation typically take blood thinners to reduce the risk of blood clots. This medication is usually tough to dose and requires frequent blood testing.

A protein embedded in blood vessel walls may be key to preventing second or third heart attacks. Researchers suspect that stopping dangerous cell growth after a vascular injury may be the key to prevention.

Stem cell transplant patients may not only be at risk during treatment. A new study suggests that a decade later they are still more susceptible to psychological conditions and chronic illness.

Heart surgery may seem frightening, but there are steps you can take to minimize complications. Researchers say one method is surprisingly easy: take aspirin during the five days leading up to cardiac surgery.

Borderline high blood pressure puts individuals at an elevated stroke risk even though patients don't formally have hypertension. Common blood pressure drugs may significantly reduce that risk.

Getting your heart into better shape isn't just about losing weight. Improving your fitness level even without weight loss reduces your risk of dying.

U.S. Food and Drug Administration officials are taking a second look at blood thinning drug Pradaxa ( dabigatran etexilate mesylate ) after reports of serious, potentially fatal, bleeding.

Previous studies have shown that omega-3 derived from fish or supplements is beneficial to heart health in men. Little research has been done to determine whether women reap the same cardiovascular protection.

Heart stem cells are in demand because damaged hearts have difficulty repairing themselves. Now researchers have identified a pool of heart stem cells capable of expanding and forming several cell types, including bone.